Padcev® (enfortumab vedotin-ejfv)
for Urothelial Cancer
Padcev (enfortumab vedotin) is an antibody-drug conjugate given as an intravenous infusion to treat adults with locally advanced or metastatic urothelial cancer. It is used with pembrolizumab (Keytruda) or alone in patients who have received prior immunotherapy and platinum-based chemotherapy or cannot receive cisplatin-based chemotherapy. Padcev targets Nectin-4 on cancer cells, delivering MMAE to disrupt microtubules, stopping cell division and promoting cell death, slowing cancer growth.
